Titan Pharmaceuticals (TTNP) announced that it has granted an exclusive license to Ocular Therapeutix Inc. (OCUL) pertaining to certain patent applications for ophthalmic uses in both humans and nonhuman animals in the territory of the United States. Under the terms of the agreement, Ocular will pay Titan an upfront licensing fee with the potential for additional payments upon reaching certain milestones.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TTNP:
